Articles

Poll

Podcasts

Slideshows

Videos

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Panelists discuss how the APPEAR-C3G trial demonstrated that iptacopan significantly reduced proteinuria by 35% at 6 months, was well tolerated with no new safety signals over 12 months, slowed glomerular filtration rate (GFR) decline, and showed a statistically significant reduction in glomerular C3 deposit scores, though detailed biopsy clearance rates were not reported.

Topline Results for the APPEAR C3G Trial: Repeat Biopsy Results

Panelists discuss how Jonathan Barratt, MBChB, PhD, FRCP, outlined the APPEAR-C3G study design, which featured a 6-month randomized period followed by an open-label extension, with primary end points including changes in proteinuria, glomerular filtration rate (GFR), and kidney biopsy features, emphasizing the study’s alignment with FDA guidance for ultrarare diseases.

APPEAR C3G Trial: Trial Design, Results, and the Importance of Patient-Led Treatment Progress

Panelists discuss how Andrew S. Bomback, MD, MPH, having been closely involved in the VALIANT trial, outlines the study’s design—a 6-month placebo-controlled period followed by open-label treatment—and highlights its significant outcomes, including over 65% proteinuria reduction, statistically significant glomerular filtration rate (GFR) improvements, and remarkable C3 clearance on kidney biopsies.

Expert Perspectives on VALIANT: Trial Design and Key Results

Pregnancies occurring during or after initial C3G presentation were at a greater risk of preeclampsia, prematurity, and renal function decline.

C3G During Pregnancy Linked to Adverse Renal, Obstetric Outcomes

Panelists discuss how the recent FDA approval of iptacopan marks a turning point in C3 glomerulopathy (C3G) treatment, with experts anticipating pegcetacoplan as the next likely candidate for approval due to promising phase 3 trial results and its transformative potential in patient outcomes.

Complement Pathway Targeting Therapies in C3G: An Overview of Clinical Trials

Panelists discuss how the evolving availability of FDA-approved medications for C3 glomerulopathy (C3G) is reshaping clinical trial design, patient enrollment, and global access, highlighting both ethical challenges and opportunities for continued research.

The Importance of Patient Participation in C3G Clinical Trials  

Panelists discuss how physicians determine when to escalate from conservative management to complement inhibitor therapy in patients with C3 glomerulopathy (C3G), considering factors like proteinuria levels, hematuria persistence, biopsy activity scores, and the critical need for improved diagnostic capabilities to guide targeted treatment selection.

When Is It Time to Escalate? Navigating C3G Treatment Decisions

Panelists discuss how improved understanding of C3 glomerulopathy (C3G) pathobiology has led to multiple clinical trials targeting complement pathways, with considerations for efficacy measurement through proteinuria reduction and kidney biopsies, while emphasizing the importance of vaccination and patient education to manage safety concerns associated with complement inhibitors.

Ongoing Clinical Trials in C3G: Safety, Efficacy, and Future Directions

The month in review spotlights renal FDA news and novel research about CKD and social determinants of health in kidney care.

Nephrology Month in Review: April 2025

Panelists discuss how educating physicians and patients about C3 glomerulopathy (C3G) presents unique challenges due to its rarity, complexity, and the critical role of renal pathologists in diagnosis while emphasizing the growing importance of understanding the complement system as new targeted therapies emerge.

Strength in Numbers: Raising Awareness of C3G and Other Rare Diseases

The HCPLive C3 glomerulopathy page is a resource for medical news and expert insights on C3G. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in C3G, and more.

C3 Glomerulopathy